Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- 11 March 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (10), 2003-2007
- https://doi.org/10.1182/blood-2009-09-245381
Abstract
Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F. To examine the order of events, we performed colony assays and genotyped TET2 and JAK2 in individual colonies. In 4 of 8 myeloproliferative neoplasm patients, we found that some colonies with mutated TET2 carried wild-type JAK2, whereas others were JAK2-V617F positive, indicating that TET2 occurred before JAK2-V617F. One of these patients carried a germline TET2 mutation. However, in 2 other patients, we obtained data compatible with the opposite order of events, with JAK2 exon 12 mutation preceding TET2 mutation in one case. Finally, in 2 of 8 patients, the TET2 and JAK2-V617F mutations defined 2 separate clones. The lack of a strict temporal order of occurrence makes it unlikely that mutations in TET2 represent a predisposing event for acquiring mutations in JAK2.Keywords
This publication has 25 references indexed in Scilit:
- TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Blood, 2009
- Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemiasLeukemia, 2009
- Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic SyndromeJournal of Clinical Oncology, 2009
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesBlood, 2009
- TET2 mutations in myelodysplasia and myeloid malignanciesNature Genetics, 2009
- Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsBlood, 2009
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AMLLeukemia, 2009
- Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlatesLeukemia, 2009
- TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)Leukemia, 2003